Trial Profile
To evaluate the efficacy and safety of Vedolizumab in refractory Inflammatory bowel disease (IBD) who had failed or lost response to prior anti-TNF therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Dec 2016
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; Therapeutic Use
- 09 Dec 2016 New trial record
- 19 Oct 2016 Results presented at the 24th United European Gastroenterology Week